New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 25mg - capsule - 25 mg - active: lenalidomide 25mg excipient: croscarmellose sodium gelatin lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 5mg - capsule - 5 mg - active: lenalidomide 5mg excipient: croscarmellose sodium gelatin lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 7.5mg - capsule - 7.5 mg - active: lenalidomide 7.5mg excipient: croscarmellose sodium gelatin iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - pramipexole hydrochloride monohydrate 0.25mg equivalent to pramipexole 0.175 mg - tablet - 0.25 mg - active: pramipexole hydrochloride monohydrate 0.25mg equivalent to pramipexole 0.175 mg excipient: colloidal silicon dioxide magnesium stearate maize starch mannitol povidone - ramipex is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - pramipexole hydrochloride monohydrate 1mg equivalent to pramipexole 0.7 mg - tablet - 1 mg - active: pramipexole hydrochloride monohydrate 1mg equivalent to pramipexole 0.7 mg excipient: colloidal silicon dioxide magnesium stearate maize starch mannitol povidone - ramipex is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - hyoscine butylbromide 20 mg/ml - solution for injection - 20 mg/ml - active: hyoscine butylbromide 20 mg/ml excipient: hydrochloric acid nitrogen sodium chloride water for injection - muscle spasm of the gastrointestinal tract

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - cefuroxime sodium 1578mg equivalent to to cefuroxime 1500mg - powder for injection - 1.5 g - active: cefuroxime sodium 1578mg equivalent to to cefuroxime 1500mg - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - cefuroxime sodium 263mg equivalent to to cefuroxime 250mg - powder for injection - 250 mg - active: cefuroxime sodium 263mg equivalent to to cefuroxime 250mg - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - cefuroxime sodium 789mg equivalent to to cefuroxime 750mg - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to to cefuroxime 750mg - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg - solution for injection - 1 mg/ml - active: granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg excipient: citric acid monohydrate hydrochloric acid sodium chloride sodium hydroxide water for injection - for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy in adults for the prevention of nausea and vomiting induced by cytotoxic chemotherapy in children